Freedom of Information Request: 0584 2019/20
University Hospitals Birmingham NHS Foundation Trust (UHB) completed a merger by acquisition of Heart of England NHS Foundation Trust (HEFT) on 1st April 2018. Due to historical differences in data collection/reporting across UHB and the former Heart of England NHS Foundation Trust this response has been provided by hospital site.
Queen Elizabeth Hospital Birmingham:
- Could you please confirm for the last three months (October to December 2019 inclusive if possible) the total biologic caseload for Crohn’s Disease, for each of the following treatments:
Adalimumab [Amgevita] – 1
Adalimumab [Hulio] – 1
Adalimumab [Humira] – 1
Adalimumab [Hyrimoz] – 1
Adalimumab [Imraldi] – 1
Infliximab [Flixabi] – 0
Infliximab [Inflectra] – 0
Infliximab [Remicade] – 0
Infliximab [Remsima] – 0
Ustekinumab [Stelara] – 1
Vedolizumab [Entyvio] – 2
- Also, could you please confirm for the last three months (October to December 2019 inclusive if possible) the total biologic caseload for Ulcerative Colitis, for each of the following treatments:
Adalimumab [Amgevita] – 0
Adalimumab [Hulio] – 0
Adalimumab [Humira] – 0
Adalimumab [Hyrimoz] – 0
Adalimumab [Imraldi] – 0
Golimumab [Simponi] – 0
Infliximab [Flixabi] – 0
Infliximab [Inflectra] – 2
Infliximab [Remicade] – 0
Infliximab [Remsima] – 0
Tofacitinib [Xeljanz] – 0
Ustekinumab [Stelara] – 0
Vedolizumab [Entyvio] – 2
If you are unable to answer my questions with breakdown by specified conditions then please provide me with the numbers of patients treated in the last 3 months (October to December 2019 inclusive if possible) with the above drugs, regardless of disease/indication.
Heartlands, Good Hope and Solihull Hospitals:
- Could you please confirm for the last three months (October to December 2019 inclusive if possible) the total biologic caseload for Crohn’s Disease, for each of the following treatments:
Adalimumab [Amgevita]
Adalimumab [Hulio]
Adalimumab [Humira]
Adalimumab [Hyrimoz]
Adalimumab [Imraldi]
Infliximab [Flixabi]
Infliximab [Inflectra]
Infliximab [Remicade]
Infliximab [Remsima]
Ustekinumab [Stelara]
Vedolizumab [Entyvio]
We are unable to provide the data by disease/indication for Heartlands, Good Hope and Solihull Hospitals – please see total treatment numbers below
- Also, could you please confirm for the last three months (October to December 2019 inclusive if possible) the total biologic caseload for Ulcerative Colitis, for each of the following treatments:
Adalimumab [Amgevita]
Adalimumab [Hulio]
Adalimumab [Humira]
Adalimumab [Hyrimoz]
Adalimumab [Imraldi]
Golimumab [Simponi]
Infliximab [Flixabi]
Infliximab [Inflectra]
Infliximab [Remicade]
Infliximab [Remsima]
Tofacitinib [Xeljanz]
Ustekinumab [Stelara]
Vedolizumab [Entyvio]
We are unable to provide the data by disease/indication for Heartlands, Good Hope and Solihull Hospitals – please see total treatment numbers below
If you are unable to answer my questions with breakdown by specified conditions then please provide me with the numbers of patients treated in the last 3 months (October to December 2019 inclusive if possible) with the above drugs, regardless of disease/indication.
Total number of patients regardless of disease/indication for October – December 2019:
ADALIMUMAB 654
GOLIMUMAB 49
INFLIXIMAB (Inflectra) 141
INFLIXIMAB (Remicade) 1
TOFACITINIB 20
USTEKINUMAB 121
VEDOLIZUMAB 62
